Rainbow Children's Medicare Valuation
Is RAINBOW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RAINBOW?
Other financial metrics that can be useful for relative valuation.
|What is RAINBOW's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does RAINBOW's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
ASTERDM Aster DM Healthcare
543308 Krishna Institute of Medical Sciences
MEDANTA Global Health
NH Narayana Hrudayalaya
RAINBOW Rainbow Children's Medicare
Price-To-Earnings vs Peers: RAINBOW is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the peer average (37.6x).
Price to Earnings Ratio vs Industry
How does RAINBOW's PE Ratio compare vs other companies in the IN Healthcare Industry?
Price to Earnings Ratio vs Fair Ratio
What is RAINBOW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||51.7x|
|Fair PE Ratio||44.3x|
Price-To-Earnings vs Fair Ratio: RAINBOW is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the estimated Fair Price-To-Earnings Ratio (44.3x).
Share Price vs Fair Value
What is the Fair Price of RAINBOW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RAINBOW (₹795.2) is trading above our estimate of fair value (₹310.04)
Significantly Below Fair Value: RAINBOW is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
|Date||Share Price||Average 1Y Price Target||Dispersion||High||Low||1Y Actual price||Analysts|
Analyst Forecast: Target price is less than 20% higher than the current share price.